{"url_path":"/sec/dmaa/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-056798-index.html","accession_number":"0001213900-26-056798","cik":"0002028614","ticker":"DMAA","issuer_name":"Drugs Made In America Acquisition Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-056798-index.html","primary_entity_key":"0002028614","primary_entity_name":"Drugs Made In America Acquisition Corp."},"word_count":46,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n \n\n \n(a)\nNone.\n\n \n\n \n(b)\nNone.\n\n \n\n  (c) During the quarter ended March 31, 2026, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading agreement” or a “non-Rule 10b5-1 trading agreement” (in each case defined in Item 408 of Regulation S-K)."}